全文获取类型
收费全文 | 15928篇 |
免费 | 769篇 |
国内免费 | 50篇 |
专业分类
耳鼻咽喉 | 340篇 |
儿科学 | 385篇 |
妇产科学 | 321篇 |
基础医学 | 2758篇 |
口腔科学 | 376篇 |
临床医学 | 1449篇 |
内科学 | 2669篇 |
皮肤病学 | 410篇 |
神经病学 | 1649篇 |
特种医学 | 866篇 |
外科学 | 2129篇 |
综合类 | 109篇 |
一般理论 | 2篇 |
预防医学 | 833篇 |
眼科学 | 544篇 |
药学 | 1045篇 |
中国医学 | 19篇 |
肿瘤学 | 843篇 |
出版年
2022年 | 99篇 |
2021年 | 177篇 |
2020年 | 112篇 |
2019年 | 197篇 |
2018年 | 253篇 |
2017年 | 196篇 |
2016年 | 305篇 |
2015年 | 309篇 |
2014年 | 367篇 |
2013年 | 461篇 |
2012年 | 871篇 |
2011年 | 809篇 |
2010年 | 518篇 |
2009年 | 518篇 |
2008年 | 704篇 |
2007年 | 813篇 |
2006年 | 857篇 |
2005年 | 877篇 |
2004年 | 819篇 |
2003年 | 718篇 |
2002年 | 781篇 |
2001年 | 362篇 |
2000年 | 287篇 |
1999年 | 296篇 |
1998年 | 218篇 |
1997年 | 182篇 |
1996年 | 163篇 |
1995年 | 133篇 |
1994年 | 112篇 |
1993年 | 107篇 |
1992年 | 160篇 |
1991年 | 161篇 |
1990年 | 163篇 |
1989年 | 173篇 |
1988年 | 169篇 |
1987年 | 135篇 |
1986年 | 119篇 |
1985年 | 140篇 |
1984年 | 124篇 |
1983年 | 92篇 |
1982年 | 78篇 |
1981年 | 90篇 |
1979年 | 118篇 |
1978年 | 86篇 |
1977年 | 93篇 |
1976年 | 80篇 |
1975年 | 83篇 |
1974年 | 86篇 |
1973年 | 77篇 |
1972年 | 88篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
41.
Christopher A. Mills Joan W. Flacke Werner E. Flacke Byron C. Bloor Marvin D. Liu 《Journal canadien d'anesthésie》1990,37(2):238-244
Reversal of opioid effects by naloxone (NX) can lead to significant cardiovascular problems. We have reported previously that hypercapnic dogs develop greater increases in blood pressure and plasma catecholamine (CA) levels than hypocapnic ones when reversed with naloxone. We have also demonstrated differences between NX and nalbuphine (NBPH) in producing excitatory adrenergic responses when administered during normocapnia. The present study was designed to investigate possible dissimilarities in cardiovascular and sympathetic events after administration of either NX or NBPH in dogs made hypercapnic following fentanyl administration. After induction of anaesthesia with thiopentone and intubation, two groups of dogs were maintained with controlled ventilation on enflurane in oxygen anaesthesia and given 50 micrograms.kg-1 fentanyl IV. This caused a significant decrease in heart rate (HR) (P less than 0.001), mean arterial blood pressure (MAP) (P less than 0.001), and plasma concentrations of norepinephrine (NE) (P less than 0.002). Then, ventilation was decreased to produce a PaCO2 of 60 mmHg; this was accompanied by a significant elevation in plasma level of both epinephrine (EPI) (P less than 0.02) and NE (P less than 0.001). Administration of 20 micrograms.kg-1 NX to six dogs resulted in immediate increases in HR (P less than 0.01) and MAP (P less than 0.01), and a further rise in CA levels to greater than pre-fentanyl baseline values. In six other dogs, NBPH (0.3 mg.kg-1) caused increases in HR (P less than 0.001) and MAP (P less than 0.001) only, and the MAP rise was significantly less than that seen in the NX group (P less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
42.
K Brismar M Gutniak G Povoa S Werner K Hall 《Journal of endocrinological investigation》1988,11(8):599-602
The serum levels of the low molecular form of insulin-like growth factor binding protein (IGFBP) was determined in 56 outpatients with diabetes mellitus by a radioimmunoassay developed for amniotic 35 kDa IGFBP. The mean level of 35 kDa IGFBP was found to be threefold higher in insulin dependent diabetes mellitus (IDDM), 112 +/- 13 ng/ml, than in age matched controls, 37 +/- 2 ng/ml, while the mean level in non-insulin dependent diabetes mellitus (NIDDM), 16 +/- 2 ng/ml, was decreased. In hospitalized IDDM patients there was a significant correlation (r = 0.91, p less than 0.01) between fasting blood-glucose and 35 kDa IGFBP levels, not found in NIDDM patients. During insulin infusion the 35 kDa IGFBP levels declined with a half-life of 60-120 min. The decline in IGFBP continued even after the establishment of steady state B-glucose at 4.7 mmol/l. In conclusion, the elevated 35 kDa IGFBP levels in IDDM can be attributed to insulin deficiency and may reflect a reduced bioavailability of the IGFs at the target cells. 相似文献
43.
O. May M.D. H. Kirkegaard Nielsen M. U. Werner 《Acta anaesthesiologica Scandinavica》1988,32(3):239-243
A new and simple acceleration transducer (ACT)–based system of neuromuscular monitoring has recently been introduced. The precision of this transducer has been evaluated as compared to a conventional force displacement transducer (FDT) in the present study. Ten progressions of spontaneous recovery from atracurium–induced block with simultaneous measurements using the ACT on one hand and the FDT on the other were studied. Five individuals undergoing elective surgery in modified neurolept anaesthesia and one ICU–patient requiring prolonged neuromuscular blockade, sedated with pentobarbital, were included. Measurements were carried out on the latter patient on 5 consecutive days. Train–of–four (TOF) stimulation was used, readings were given in twitch heights (TH) (Tl/control value), and when four responses were obtained in TOF–ratios (T4/T1). Linearity was achieved after logit–transformation and the values regressed on time for each progression of recovery. Analysis of variance was applied to the regressions for the TH and TOF–ratio readings of each transducer. No significant differences were found, either between variation due to differences between slopes or variation due to technical error between the two transducers. The study indicates that the ACT is equal to the FDT with regard to precision in clinical recordings on atracuriumrelaxed individuals. 相似文献
44.
45.
Werner Steimer Julia M Potter 《Clinica chimica acta; international journal of clinical chemistry》2002,315(1-2):137-155
BACKGROUND: Pharmacogenetics is the science of the influence of heredity on pharmacological response. ISSUES: The cost of severe adverse drug reactions in individuals has been estimated in the US alone to be in excess of US$4 billion. It has been argued that in a significant proportion of cases, the efficacy and toxicity profiles of drug therapy would be substantially improved in individuals if characteristics due to genetic variation were taken into account. Methods are now available, which make screening for susceptibility feasible. CONCLUSIONS: There are several therapeutic areas in which screening may give rise to significant improvements in outcome with cost-benefits to both the individual and the community. However, there is currently a lack of data on which cost-benefit analysis can be based. The challenge is to provide this information for new drugs, and for drugs with established therapeutic roles. 相似文献
46.
47.
48.
J. Viby Mogensen M.D. Ph.D. E. Jensen M. Werner H. Kirkegaard Nielsen 《Acta anaesthesiologica Scandinavica》1988,32(1):45-48
A new method for monitoring neuromuscular function based on measurement of acceleration is presented. The rationale behind the method is Newton's second law, stating that the acceleration is directly proportional to the force. For measurement of acceleration, a piezo-electric ceramic wafer was used. When this piezo electrode was fixed to the thumb, an electrical signal proportional to the acceleration was produced whenever the thumb moved in response to nerve stimulation. The electrical signal was registered and analysed in a Myograph 2000 neuromuscular transmission monitor. In 35 patients anaesthetized with halothane, train-of-four ratios measured with the accelerometer (ACT-TOF) were compared with simultaneous mechanical train-of-four ratios (FDT-TOF). Control ACT-TOF ratios were significantly higher than control FDT-TOF ratios: 116 +/- 12 and 98 +/- 4 (mean +/- s.d.), respectively. In five patients not given any relaxant during the anaesthetic procedure (20-60 min), both responses were remarkably constant. In 30 patients given vecuronium, a close linear relationship was found during recovery between ACT-TOF and FDT-TOF ratios. It is concluded that the method fulfils the basic requirements for a simple and reliable clinical monitoring tool. 相似文献
49.
Werner Tolksdorf 《Schmerz (Berlin, Germany)》1988,2(2):105
Ohne Zusammenfassung 相似文献
50.
Christopher G Goetz Stanley Fahn Pablo Martinez-Martin Werner Poewe Cristina Sampaio Glenn T Stebbins Matthew B Stern Barbara C Tilley Richard Dodel Bruno Dubois Robert Holloway Joseph Jankovic Jaime Kulisevsky Anthony E Lang Andrew Lees Sue Leurgans Peter A LeWitt David Nyenhuis C Warren Olanow Olivier Rascol Anette Schrag Jeanne A Teresi Jacobus J Van Hilten Nancy LaPelle 《Movement disorders》2007,22(1):41-47
This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS-UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve problematic areas. An MDS-UPDRS committee prepared the revision using the recommendations of the published critique of the scale. Subcommittees developed new material that was reviewed by the entire committee. A 1-day face-to-face committee meeting was organized to resolve areas of debate and to arrive at a working draft ready for clinimetric testing. The MDS-UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Experiences of Daily Living; III, Motor Examination; and IV, Motor Complications. All items have five response options with uniform anchors of 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Several questions in Part I and all of Part II are written as a patient/caregiver questionnaire, so that the total rater time should remain approximately 30 minutes. Detailed instructions for testing and data acquisition accompany the MDS-UPDRS in order to increase uniform usage. Multiple language editions are planned. A three-part clinimetric program will provide testing of reliability, validity, and responsiveness to interventions. Although the MDS-UPDRS will not be published until it has successfully passed clinimetric testing, explanation of the process, key changes, and clinimetric programs allow clinicians and researchers to understand and participate in the revision process. 相似文献